Quantum-Si has delayed the commercial launch of its Proteus protein sequencing platform to Q2 2027 and implemented a 20% workforce reduction to extend its cash runway into Q4 2028. The proteomics technology company reported second quarter revenue of $344,000, down from $591,000 in the prior year period. The company posted a net loss of $23.5 million for the quarter, compared to $28.8 million a year earlier. The launch delay incorporates an additional design cycle focused on manufacturing readiness and system repeatability. Chief executive Jeff Hawkins said testing has reinforced confidence in the technology, whilst the extra cycle will strengthen commercialisation readiness. Quantum-Si highlighted a $4 billion annual market opportunity in non-human proteomics, identified through work on agricultural applications and pathogen detection. The workforce reduction is expected to generate approximately $12 million in annualised savings whilst maintaining critical development resources.

Quantum-Si (NASDAQ:QSI) announces quarterly earnings results. August 13, 2026 Key points. * Quantum-Si met earnings expectations, reporting a quarterly loss of $0.11 per share, while revenue of $0.34 million exceeded analysts' $0.30 million forecast. The company continued to report significant net losses and negative return on equity. * Shares fell to $0.79, near the lower end of their 52-week range of $0.69 to $3.10. Analysts maintain a consensus "Reduce" rating with a $1.00 price target, while Weiss Ratings downgraded the stock to "sell (e+)." * Institutional ownership stands at 39.90%, with investors including Millennium Management, State Street, Bank of America and Geode Capital increasing or initiating positions in Quantum-Si. * MarketBeat previews the top five stocks to own by September 1st. Quantum-Si (NASDAQ:QSI - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11), FiscalAI reports. The business had revenue of $0.34 million for the quarter, compared to analysts' expectations of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. Quantum-Si price performance. NASDAQ QSI traded down $0.05 during trading hours on Thursday, reaching $0.79. The company's stock had a trading volume of 4,129,465 shares, compared to its average volume of 4,733,177. The firm has a market capitalization of $172.03 million, a price-to-earnings ratio of -1.55 and a beta of 3.24. The company's 50-day moving average is $0.88 and its two-hundred day moving average is $0.93. Quantum-Si has a 1-year low of $0.69 and a 1-year high of $3.10. Wall Street analyst weigh in. Separately, Weiss Ratings cut shares of Quantum-Si from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $1.00. Institutional inflows and outflows. Several large investors have recently made changes to their positions in QSI. Millennium Management LLC acquired a new stake in shares of Quantum-Si in the first quarter valued at about $4,721,000. State Street Corp boosted its holdings in Quantum-Si by 26.5% in the 4th quarter. State Street Corp now owns 3,562,721 shares of the company's stock worth $3,919,000 after buying an additional 745,231 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Quantum-Si in the 3rd quarter worth about $865,000. Bank of America Corp DE increased its stake in Quantum-Si by 426.6% during the 2nd quarter. Bank of America Corp DE now owns 465,999 shares of the company's stock worth $913,000 after buying an additional 377,504 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Quantum-Si by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company's stock worth $4,527,000 after buying an additional 367,206 shares in the last quarter. 39.90% of the stock is owned by institutional investors and hedge funds. Quantum-Si company profile. Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company's core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods. Quantum-Si's product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Quantum-Si, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum-Si wasn't on the list. While Quantum-Si currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Quantum-Si reported first-quarter 2026 revenue of $258,000 and said the year would focus on development and market preparation for its next-generation Proteus protein sequencing platform, which is expected to launch commercially by year-end. The company completed sequencing on fully integrated Proteus instruments during the quarter, a milestone CEO Jeff Hawkins described as a significant de-risking event. Quantum-Si increased detectable amino acids from 15 to 17 within four months and aims to detect 18 amino acids at launch and all 20 during 2026. Proteus is expected to offer advantages over the current Platinum system, including automation, higher throughput and longer peptide read lengths. The company is also developing post-translational modification analysis capabilities for the platform.